Welcome to our dedicated page for Avalon Globocare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon Globocare stock.
Avalon GloboCare Corp. (NASDAQ: ALBT) generates news across precision diagnostics, cellular therapy intellectual property, generative AI software, and commercial real estate. Company press releases describe Avalon as a commercial‑stage developer of precision diagnostic consumer products, with a flagship focus on the KetoAir™ handheld breathalyzer for ketogenic health management. News coverage frequently highlights deployments of KetoAir™ in wellness initiatives, first responder programs, and international online sales channels.
Investors following ALBT news will see updates on distribution agreements, affiliate marketing programs, and partnerships that incorporate KetoAir™ as a real‑time metabolic monitoring tool. Recent announcements include collaborations with Saga Health Corporation and SpecialtyHealth, Inc. for first responder wellness programs, as well as expansion of KetoAir™ availability into the United Kingdom through online sales. Avalon also reports on its co‑development agreement with Qi Diagnostics Limited to create a VOC nanosensor‑based cannabis breathalyzer aimed at supporting detection of potential cannabis‑impaired driving.
Beyond diagnostics, Avalon’s news flow includes developments in its cellular therapy intellectual property portfolio, such as the issuance of a Hong Kong patent for proprietary CAR‑T and CAR‑NK cell technology co‑developed with Arbele Limited. The company also issues updates on its acquisition of RPM Interactive, Inc. and the Catch‑Up generative AI SaaS platform, which is designed to automate short‑form video creation and support marketing for KetoAir™ and other consumer health products.
Regulatory and corporate actions also feature in ALBT news, including SEC filings, financing transactions, Nasdaq listing compliance updates, and progress on the proposed merger with YOOV Group Holding Limited. Readers can use this news stream to monitor how Avalon’s precision diagnostics, AI‑driven software, cellular therapy IP, and capital markets activities evolve over time.
Avalon GloboCare (NASDAQ: ALBT) announced that it has received a notice from Nasdaq on May 22, 2024, stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its failure to file the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024.
The notice does not affect the immediate listing or trading of Avalon's common stock. The company has until July 22, 2024, to submit a plan to regain compliance. If accepted, Nasdaq may allow until November 18, 2024, for Avalon to file the report and regain compliance. Avalon is working to finalize and file the report promptly.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.